Related Experiment Video

Updated: Jun 23, 2026

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection

Gowdara Divakara Murthy1, Khoa Vu, Sushma Venugopal

  • 1Stratton VA Medical Center, Albany, NY 12208, USA. murthy.divakara@va.gov

European Journal of Gastroenterology & Hepatology
|April 29, 2009
PubMed

Insights

Hyperlipidemia is common in hepatitis C (HCV) patients, especially those with active viral RNA. While many are eligible for treatment, under-treatment persists, indicating a need for improved cardiovascular risk management in this population.

Area of Science:

  • Hepatology
  • Cardiology
  • Infectious Diseases

Background:

  • Chronic hepatitis C (HCV) infection is frequently associated with hyperlipidemia and glucose intolerance.
  • Managing hyperlipidemia in HCV patients is crucial due to increased cardiovascular risk.
  • Under-treatment of hyperlipidemia in HCV patients may stem from concerns about liver function.

Purpose of the Study:

  • To determine the prevalence of hyperlipidemia in patients with hepatitis C.
  • To assess the extent of hyperlipidemia under-treatment in this population.
  • To evaluate cardiovascular risk factors and treatment patterns in HCV patients with hyperlipidemia.

Main Methods:

  • Retrospective analysis of patient records from Stratton Veterans Affairs Medical Center.
  • Data collection included demographics, HCV status, comorbidities, medications, and laboratory values (hepatic function, glucose, lipids).
  • Prevalence of hyperlipidemia and cardiovascular risk factors were analyzed, along with lipid-lowering treatment rates.

Main Results:

  • Hyperlipidemia was present in 70.5% of 891 HCV patients, with highest prevalence in those with detectable viral RNA.
  • Approximately 45.2% of hyperlipidemic patients were eligible for treatment.
  • Treatment rates for hyperlipidemia varied, with 65.1% of high-risk patients (diabetes/arterial disease) and 43.3% of lower-risk patients receiving medication.

Conclusions:

  • Hyperlipidemia is highly prevalent in HCV patients, particularly those with active viral replication.
  • A significant proportion of HCV patients with hyperlipidemia are eligible for, but may not receive, appropriate treatment.
  • Improved management strategies are needed to address hyperlipidemia and reduce cardiovascular risk in the HCV population.
Abstract

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...